

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

**PARTIAL REPURCHASE AND CANCELLATION OF
RMB1,916.0 MILLION US\$-SETTLED ZERO COUPON
CONVERTIBLE BONDS DUE 2026 ON THE OPEN MARKET
(STOCK CODE: 40733)**

Reference is made to the announcements (the “**Announcements**”) of Pharmaron Beijing Co., Ltd. (the “**Company**”) dated June 8, 2021, June 9, 2021, June 11, 2021, June 18, 2021 and June 21, 2021 regarding the issuance of the RMB1,916.0 million US\$-settled zero coupon convertible bonds by the Company due 2026 (the “**Series 2 Bonds**”) and the announcements of the Company dated May 30, 2022, June 13, 2022, March 30, 2023, June 20, 2023, July 26, 2023 and January 12, 2024 regarding the shares convertible, certain conversion price adjustments and repurchase of the Series 2 Bonds, unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company hereby announces that as of the date of this announcement, the Company has further repurchased an aggregate principal amount of RMB160 million of the Series 2 Bonds (the “**Repurchased Series 2 Bonds**”) with the rights to convert into 1,924,215 shares of the Company, representing approximately 8.4% of the aggregate principal amount of the Series 2 Bonds originally issued since January 12, 2024. In aggregate, the Company has in aggregate repurchased RMB865 million of Series 2 Bonds, representing approximately 45.1% of the original principal amount. The board of directors of the Company (the “**Board**”) considered that there will be no material impact on the financial position of the Company as a result of the aforesaid repurchase of the Repurchased Series 2 Bonds. The Board believes that the repurchase and subsequent cancellation of the Repurchased Series 2 Bonds reflects the Company’s confidence in its long-term business prospects and could also enhance the return to the shareholders of the Company.

The Company expects to cancel the previously repurchased Series 2 Bonds as soon as possible. Immediately after the cancellation, an aggregate principal amount of RMB1,051 million of the Series 2 Bonds will remain outstanding.

Pursuant to Rule 37.48(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Company will make a further announcement for every subsequent 5% interval of the initial aggregate principal amount of the Series 2 Bonds that have been redeemed or cancelled in accordance with the terms and conditions of the Series 2 Bonds.

Holders of the Series 2 Bonds and other securities of the Company as well as potential investors should exercise caution when dealing in securities of the Company.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
January 15, 2024

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Ms. Li Lihua, Mr. Zhou Qilin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.